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ABSTRACT  1 
Scope: This work aimed at investigating absorption, metabolism and bioavailability of 2 
phenolic compounds after consumption of wholegrain bread or bread enriched with an 3 
aleurone fraction. 4 
Methods and results: Two commercially available breads were consumed by 15 participants 5 
on three occasions and matched for either the amount of ferulic acid in the bread or the 6 
amount of bread consumed. Urine was collected for 48 h from all the volunteers for 7 
phenolic metabolite quantification. Blood samples were collected for 24 h following bread 8 
consumption in 5 participants. A total of 12 and 4 phenolic metabolites were quantified in 9 
urine and plasma samples, respectively. Metabolites were sulfate and glucuronic acid 10 
conjugates of phenolic acids, and high concentrations of ferulic acid-4’-O-sulfate, 11 
dihydroferulic acid-4’-O-sulfate and dihydroferulic acid-O-glucuronide were observed. The 12 
bioavailability of ferulic acid was significantly higher from the aleurone-enriched bread 13 
when all ferulic acid metabolites were accounted for. 14 
Conclusions: The study shows that low amounts of aleurone-enriched bread resulted in 15 
equivalent plasma levels of ferulic acid as wholegrain bread. This could suggest that, if the 16 
absorbed phenolic metabolites after wholegrain product intake exert health benefits, equal 17 








levels could be reached through the consumption of lower doses of refined products 18 
enriched in aleurone fraction. 19 
The study shows that low amounts of bread enriched in aleurone, the metabolically active innermost 20 
part of the bran, resulted in equivalent plasma levels of ferulic acid as wholegrain bread. This could 21 
suggest that, if the absorbed phenolic metabolites after wholegrain product intake exert health 22 
benefits, equal levels could be reached through the consumption of lower doses of refined products 23 
enriched in aleurone fraction. 24 
 
1 INTRODUCTION 25 
Increasing epidemiological, mainly observational, evidence suggests that wholegrain cereal 26 
consumption is linked to a reduction in the risk of chronic and degenerative diseases such as 27 
type 2 diabetes, cardiovascular disease, obesity, and cancer [1-4]. Although the mechanisms 28 
proposed for potential preventative effects have not been elucidated and remain 29 
speculative, the amounts of dietary fiber, vitamins, minerals and phytochemicals in 30 
wholegrain cereal appear to have key roles [5]. Inflammation might mediate the process, as 31 
suggested by the effect of wholegrain cereals on inflammatory markers such as C-reactive 32 
protein (CRP), TNF-α, plasminogen activator inhibitor-1 and interleukin (IL)-6 [6-9]. Despite 33 
the evidence and the high levels of bioactive nutrients and non-nutrients, wholemeal cereal 34 
consumption remains lower than recommended in guidelines. In the United States, the 35 
consistent promotion of wholegrain products led to a 23.4% rise in consumption from 2008 36 
to 2010.  However, the present average intake of 14 g/day is still considerably lower than 37 
the recommended intake of at least 48 g/day [10].  38 
Whole-wheat is the main wholegrain cereal consumed in Western countries and represents 39 
an important source of dietary fiber [11]; minerals such as potassium, phosphorus, 40 
magnesium; vitamins, mainly niacin and folate; and phenolic compounds [12]. Phenolic 41 








compounds in wheat bran include primarily hydroxycinnamic acids among which ferulic acid 42 
is the most abundant representing the 70 to 90%, caffeic acid, p-coumaric acid, sinapic acid, 43 
and benzoic acid derivatives, including protocatechuic acid, p-hydroxybenzoic acid, salicylic 44 
acid, vanillic acid; and syringic acid [12, 13]. The whole-wheat kernel is usually processed to 45 
obtain the bran fraction which contains 45–50% of the aleurone layer. The aleurone layer is 46 
a metabolically active monolayer that is the innermost part of the bran and represents 5–8% 47 
of the wheat kernel [12, 14]. The aleurone layer is usually removed during milling for its firm 48 
attachment to the external integuments [15]. However, the aleurone has a high content of 49 
fiber, protein, minerals, phytates, B vitamins (niacin, riboflavin and folate), lipidic 50 
compounds, plant sterols, and phenolic compounds [12]. Moreover, being protected from 51 
the environment, its content of pollutants such as pesticide residues, aflatoxins and heavy 52 
metals is reduced compared to the pericarp [16]. Due to its high content in nutrients and 53 
low level of contaminants, the development of new techniques to separate the aleurone 54 
from other bran layers has been actively sought by the food industry [16].  55 
Most phenolic acids exist in the aleurone layer and in the wholegrain in three forms; soluble 56 
free acids; soluble conjugated moieties esterified to sugars or other low molecular weight 57 
compounds; and insoluble bound moieties that are esterified to the fiber fraction, mainly 58 
arabinoxylans. Ferulic acid, in particular, occurs partly in the free glycosylated form, but 59 
principally (∼92%) covalently esterified with plant cell wall polysaccharides by O-5 position 60 
linkage [11, 17]. Moreover, ferulic acid undergoes dimerization in planta to form oligomers, 61 
namely dihydrodiferulic acids (ferulic acid dimers) and ferulic trimers [18, 19]. The linkage of 62 
hydroxycinnamates with the fiber fraction reduces the bioaccessibility [13] and 63 
bioavailability [20] of the phenolic fraction.  Although, recently proposed technological 64 








bioprocessing demonstrated the capacity to improve ferulic bioaccessibility [13, 21], it is 65 
necessary to consider the complex set of transformations that cereal phenolics are 66 
subjected to within the human body following ingestion.  67 
Several studies have demonstrated that phenolic compounds are extensively metabolized 68 
and heavily modified after ingestion. After polyphenol-rich food intake, circulating phase-II 69 
and microbiota-derived catabolites are predominant, whereas native compounds rarely 70 
appear in circulation. Minor chemical modifications in the small intestine include the 71 
formation of aglycones that undergo conjugation by phase II enzymes at the enterocyte, in 72 
the liver and at the tissue level after absorption [22, 23]. In contrast, a substantial amount of 73 
unmodified native compounds reach the colon where they are subjected to microbial 74 
catabolism that results in structurally modified catabolites (23). These catabolites are then 75 
absorbed through the portal circulation and undergo phase II metabolism [24]. Generally, 76 
the phenolic-fiber linkage in wholegrain products prevents almost all the phenolics from 77 
upper intestine absorption. The vast majority of these molecules reach the colon where the 78 
gut microbiota -glucosidase and esterase activity permits a slow and continuous release of 79 
bound phenolics and ferulic acid [25]. The continuous release causes prolonged metabolite 80 
circulation in the bloodstream, which could explain the health benefits correlated with 81 
sustained wholegrain consumption [11].  82 
Building on previous in vitro [26, 27] and animal studies [28] performed by our group the 83 
aim of this investigation  was to assess the human absorption, metabolism and 84 
bioavailability of phenolic compounds following the consumption of whole-wheat.  We also 85 
aim to measure and compare the concentration of metabolites in urine and plasma 86 
following the consumption of wholegrain bread or bread enriched with aleurone fraction. 87 









2 MATERIALS AND METHODS 89 
2.1 Participants 90 
Fifteen participants were recruited to take part in the study. Selected participants were 8 91 
males and 7 females, 26 ± 4 years old, 62.4 ± 13.5 kg, 1.7 ± 0.1 m and 21 ± 3 kg/m2 (data 92 
expressed as mean ± SD). Exclusion criteria included: not being pregnant or nursing; not 93 
being diagnosed with gluten intolerance or metabolic disorders such as hypertension, 94 
dyslipidemia, glucose intolerance or diabetes; non users of vitamin/mineral/micronutrient 95 
supplementation, and not taking any medication/drugs or antibiotic therapy. All participants 96 
were informed about the purpose of the study and provided written informed consent 97 
before their inclusion in the trial. Relevant principles of Good Clinical Practice were followed 98 
throughout the study. The study was approved by the Ethics Committee for Parma Hospital 99 
and University and registered on ClinicalTrials.gov, identification number: NCT02353234. A 100 
flow diagram of the progress through the phases of the trial is reported in supporting 101 
information figure 1. 102 
 103 
2.2 Study design 104 
In a single-blind, randomized, crossover study design two commercially available breads 105 
(Barilla S.P.A.) were consumed by each participant on three separate occasions. The 106 
phenolic composition and concentrations of the two breads were first confirmed [27] prior 107 
to meal portion calculation. The nutritional values and the ferulic acid content per portion 108 
are reported in Table 1. 109 








Each participant was tested under three acute treatments that differed for the amount of 110 
ferulic acid or the bread quantity consumed. Each acute feeding experiment was separated 111 
by a minimum 1-week washout period. The bread products consumed consisted of: WGB - 112 
94 g of wholegrain bread containing approximately 87 mg of total ferulic acid; AB-94 - 94 g 113 
of a commercial wheat bread enriched in aleurone fraction (6% w/w of the inner part of 114 
aleurone [26]) containing approximately 43 mg of total ferulic acid, which matches WGB for 115 
total bread consumed; AB-190 - 190 g of a commercial bread enriched in aleurone fraction 116 
(6% w/w of the inner part of aleurone [26]), containing approximately 87 mg of total ferulic 117 
acid, which matches WGB for the total amount of ingested ferulic acid. 118 
Participants were asked to consume a polyphenol free diet two days prior to and two days 119 
after laboratory visits. A list of permitted and forbidden foods was supplied to facilitate 120 
participant adherence to the dietary restrictions.  Additionally, a food diary was provided to 121 
record all meals and to check for compliance to the recommended diet. During the 122 
laboratory visits participants collected their urine following fasting (t0), and after product 123 
consumption at: 0-3, 3-6, 6-10, 10-14, 14-24, 24-28, 28-34 and 34-48 h. The urine volumes 124 
were recorded and two aliquots of 2 mL each were stored at −80 °C until analysis. Five 125 
randomly selected participants provided 3 mL blood samples taken at fasting (t0) and at 30 126 
min, 1 h, 2 h, 4 h, 7 h, and 24 h following bread consumption. Blood was collected in K2EDTA 127 
tubes, centrifuged for 15 min at 4,000 rpm and ≈ 1.2 mL of plasma was separated and 128 
stored at −80 °C until analysis. The study design is shown in Fig. 1.   129 
 130 
2.3 Chemicals 131 








All chemicals and solvents were of analytical grade. All solvents and reagents were 132 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Vanillic acid (3-methoxy-4-133 
hydroxybenzoic acid), 3-hydroxybenzoic, 4- hydroxybenzoic, protocatechuic acid (3,4-134 
dihydroxybenzoic acid), 3’,4’-dihydroxyphenylacetic acid, 3-(3’-hydroxyphenyl)propionic 135 
acid, 3-(4’-hydroxyphenyl)propionic acid, hippuric acid, 4-hydroxyhippuric acid, and 136 
ferouloylglycine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ferulic acid-4’-O-137 
sulphate disodium salt, isoferulic acid-3’-O-β-D-glucuronide, dihydroferulic acid 4’-O-sulfate 138 
sodium salt, dihydroisoferulic acid 3-O-β-D-Glucuronide, and dihydrocaffeic acid-3’-O-139 
sulphate sodium salt were purchased from Toronto Research Chemicals (Toronto, Ontario, 140 
Canada). Ultrapure water from MilliQsystem (Millipore, Bedford, MA, USA) was used 141 
throughout the experiment. 142 
 143 
2.4 Urine and plasma extraction 144 
Urine samples were centrifuged at 14,000 rpm for 10 min and 700 μL of supernatant was 145 
diluted 1:2 (v/v) adding acidified water (0.1% formic acid v/v). Samples were then filtered 146 
through a 0.45 μm nylon filter before analysis. 147 
 148 
Plasma samples were extracted for analysis following the method previously reported by 149 
Renouf [29]. Briefly, 400 μL of plasma was added to 1.2 mL of ethanol. Samples were 150 
vortexed for 5 min, centrifuged at 14,000 rpm for 10 min and 1.3 mL of supernatant was 151 
dried under a rotary-vacuum evaporation. The pellet was re-suspended with 65 μL of 152 
acidified water (1% formic acid)/methanol (50:50, v/v) and samples were vortexed again to 153 
dissolve the pellet and finally centrifuged at 14,000 rpm for 5 min prior to analysis. 154 









2.5 uHPLC/MSn Analysis 156 
Urine and plasma samples were analyzed by ultra-high performance liquid chromatography 157 
coupled with mass spectrometry (uHPLC/MS) to identify and quantify the phenolic 158 
metabolites after bread consumption. An Accela ultra-high performance liquid 159 
chromatography (uHPLC) 1250 apparatus equipped with a linear ion trap mass spectrometer 160 
(LIT-MS) (LTQ XL, Thermo Fisher Scientific Inc., San Jose, CA, USA) fitted with a heated-ESI 161 
(H-ESI-II) probe (Thermo Fisher Scientific Inc.) was used. Compound separations were 162 
performed with a XSELECTTM HSS PFP column (50 x 2.1 mm), 2.5 μm particle size (Waters, 163 
USA). A preliminary analysis was carried out in full scan, data-dependent MS3 mode, 164 
scanning from a mass to charge (m/z) of 100 to 800 to perform a preliminary assessment of 165 
the main phenolic metabolites present in the samples. On the basis of the obtained 166 
information, a second preliminary analysis was carried out in full MS2 and MS3 mode to 167 
confirm the identification of the detected metabolites and to record the retention time. 168 
Finally, quantification of all metabolites in biological samples was achieved using the single 169 
reaction monitoring (SRM) mode. The analyses were carried out in negative ionization 170 
mode, with a capillary temperature of 275°C, while the source was set at 250°C. The sheath 171 
gas flow was 40 units, while auxiliary and sweep gases were set to 5 units. The source 172 
voltage was 3 kV. The capillary voltage and tube lens were −9 and −53 V, respectively. For 173 
chromatographic analysis, the mobile phase, pumped at a flow rate of 0.3 mL/min, was 174 
composed of acetonitrile containing 0.1% formic acid (solvent A) and 0.1% formic acid in 175 
water (solvent B). A linear gradient bringing A from 5 to 50% over 6.5 min was carried out 176 
for separation. All metabolites were fragmented using a collision-induced dissociation (CID) 177 








of 30, using helium gas for the collision. Where available, phenolic acid catabolites were 178 
quantified using a calibration curve prepared with the standard compound. When not 179 
available, the conjugated metabolites were quantified with the most structurally similar 180 
compound (Table 2).  181 
 182 
2.6 Statistical analysis and absorption kinetic parameters 183 
Based on available published data [30], using an F test and an ANOVA test with repeated 184 
measures, it was estimated that 12 participants in each treatment group would give 185 
sufficient power (α error of 0.05, 80% power) to detect a significant difference of 5.0 mol 186 
of excreted ferulic acid.  187 
Urine and plasma data were analyzed with a statistical software (SPSS, Chicago, IL, USA, 188 
version 21). All data were expressed as mean values ± SEM. A general linear model repeated 189 
measures (ANOVA, LSD post-hoc test) analysis was performed to compare each metabolite 190 
among the three treatments. Statistical significance was set at p < 0.05. Kinetic parameters 191 
of the plasmatic metabolites detected after bread consumption, including area under curve 192 
(AUC), plasma maximum concentration (Cmax), time to reach the maximum plasma 193 
concentration (Tmax), and, when available, apparent half-life (T1/2) were calculated by means 194 
of pharmacokinetic functions for Microsoft Excel. Data on pharmacokinetic parameters 195 
were presented as mean values ± SEM. 196 
 197 
3 RESULTS 198 
All participants consumed the control bread (wholegrain bread) once and the breads 199 
enriched in aleurone fraction twice for a total of three experimental trials. The portion of 200 








each meal was calculated to ensure that the same dose of ferulic acid (WGB vs AB-190) or 201 
the same quantity of bread (WGB vs AB-94) was administered. This approach allowed us to 202 
determine the bioavailability of ferulic acid in wholegrain products compared to aleurone-203 
rich bread, and to test the possible influence of the consumed dose on the phenolic acid 204 
absorption and metabolism. All participants consumed the entirety of provided meals, 205 
which were well tolerated. 206 
Using LC-MS analysis, 12 metabolites were identified, or tentatively identified, and 207 
quantified in urine samples, whereas only 4 metabolites were quantifiable in plasma 208 
samples. The spectrometric characteristics of the detected catabolites are reported in Table 209 
3. The phenolic composition of the tested products were mostly free or bound phenolic 210 
acids [27] with no parent compound detected in the analyzed urine and plasma samples 211 
 212 
3.1 Identification and Quantification of Urinary Metabolite 213 
Among the 12 quantified urinary metabolites, 7 compounds were detected as sulfate 214 
conjugates and one as a glucuronide conjugate, highlighting the importance of the 215 
interaction of native phenolic compounds with intestinal and hepatic sulfotransferases 216 
(SULTs) and uridine-5’-diphosphate glucuronosyltransferases (UGTs). The presence of only 217 
one glucuronidated metabolite could suggest a minor interaction of phenolic acids of 218 
wholegrain and aleurone fractions with UGTs, compared with SULTs [28]. Besides the sulfate 219 
and glucuronidated forms, one metabolite was detected in its free, aglyconic form, and 220 
three compounds were found as nitrogen-containing conjugates, a reaction strictly linked to 221 
microbial metabolism [31].  222 








The most abundant metabolites in terms of cumulative excretion appeared to be hippuric 223 
acid and hydroxyhippuric acid. Two isomers of hydroxyhippuric acid were detected in all 224 
samples, but they were quantified together using the available standard. These nitrogen-225 
containing metabolites were monitored due to their possible origin from phenolic 226 
compounds. However, the initial amount and the trend of the excretion curves suggests 227 
several potential origins as previously reported *23+ (Supporting information Fig. 2).  228 
Since ferulic acid is the main phenolic compound, both in wholegrain and in aleurone-rich 229 
bread, high concentrations of ferulic acid metabolites (ferulic acid-4’-O-sulfate, 230 
dihydroferulic acid-4’-O-sulfate and dihydroferulic acid-O-glucuronide) were recovered in 231 
urine samples (Fig. 2). If the ferulic acid-4’-O-sulfate (Fig. 2a) indicates an interaction of the 232 
native compound with the SULTs, the dihydroferulic metabolites (Fig. 2b and 2c) provides 233 
evidence of a microbial action on the double C-C bond prior to hepatic sulfation or 234 
glucuronidation. Colonic catabolism also resulted in the production of feruloylglycine *32+ 235 
(Fig. 2d). Fig. 3 shows the cumulative excretion of dihydrocaffeic acid sulfate (Fig. 3a) and 236 
sinapic acid sulfate (Fig. 3b), with the latter tentatively identified due to the lack of a 237 
commercial standard. As previously reported for ferulic acid colonic metabolites, the 238 
importance of the microbiota on the biotransformation of native phenolic compounds was 239 
demonstrated by the presence of dihydrocaffeic acid sulfate and other low molecular weight 240 
metabolites such as vanillic acid-4-O-sulfate (Fig. 3c) and hydroxybenzoic acid sulfate (Fig. 241 
3d), and of a negligible amount of 3-(phenyl)propionic acid-O-sulfate (Supporting 242 
information Fig. 2c). These metabolites could originate from all the native phenolic acids in 243 
the diet, not specifically to ferulic acid.  For this reason, these specific metabolites cannot be 244 
taken into account when ferulic acid bioavailability is evaluated. Finally, 3’,4’- 245 








dihydroxyphenylacetic acid was the only identified unconjugated compound (Supporting 246 
information Fig. 2d). The concentration in urine appeared to increase throughout the 48 h 247 
sampling period with no noticeable difference across the products ingested.   248 
By observing the slopes of the 48-h cumulative curves, the metabolic origin of each 249 
metabolite could be interpreted. Specifically, a steep slope recorded within the 0-3 h time 250 
period is suggestive of early absorption in the small intestine, and of a subsequent 251 
conjugation at the enterocyte or hepatic level. Hence, ferulic acid-4’-O-sulfate was the only 252 
metabolite derived from this metabolic path, indicating that the native compound could be 253 
partially absorbed in the small intestine (Fig. 2a). An increase in the slope at 3-6 h indicates a 254 
release of the most accessible fiber-linked-phenolic compounds by microbiota enzymatic 255 
activity. The release of native compounds in the colon led to increased absorption and 256 
further conjugation. For example, ferulic acid-4’-O-sulfate (Fig. 2a), sinapic acid sulfate (Fig. 257 
3b) and hydroxybenzoic acid sulfate (Fig. 3b) curves exhibited a increased rate of appearance 258 
within 3 and 6 h. Finally, increasing slopes detected from 6 to 48 h explain a deeper 259 
microbiota catabolism. In particular, metabolites excreted during these excretion periods 260 
could be associated with i) a long transient time in the large intestine, according to normal 261 
metabolism of dietary fiber-rich products [33], which caused a slower release of less 262 
accessible fiber-linked phenolics; ii) the microbial enzymatic activity needed to convert the 263 
released phenolic compounds into lower molecular weight molecules (as vanillic acid, 264 
hydroxybenzoic acid (Fig. 3c and d), 3-(phenyl)propionic acid (Supporting information Fig. 265 
2c)), or into nitrogen-containing conjugates (hippuric acid, hydroxyhippuric acid (Supporting 266 
information Fig. 2a and 2b) and feruloylglycine (Fig. 2d)), or into reduced forms 267 








(dihydrocaffeic acid (Fig. 3a) and dihydroferulic acid (Fig. 2b and 2c)); or iii) the hepatic 268 
SULTs and UGTs activity on phenolics absorbed from the colon. 269 
Observation of the 48-h urinary excretion (Fig. 2, 3 and Supporting information Fig. 2) 270 
suggests that the consumption of AB-190 (bread enriched with aleurone fraction that 271 
contained the same dose of ferulic acid of the wholegrain bread) is generally linked to 272 
higher excretion of almost all the detected metabolites, with peculiar differences for 273 
feruloylglycine, hippuric acid, dihydrocaffeic acid sulfate, and sinapic acid sulfate.  274 
 275 
3.2 Bioavailability 276 
To calculate the bioavailability of specific wheat phenolics, we have computed the ratio 277 
between the total metabolite 48h urinary excretion and the total intake of parent 278 
compounds through the three fed bread portions. 279 
Although the 48-h cumulative excretion of dihydrocaffeic acid sulfate and sinapic acid 280 
sulfate appeared significantly higher after the consumption of the aleurone enriched bread, 281 
the bioaccessibility and bioavailability of caffeic or sinapic acid cannot be quantified as the 282 
portion meal was not standardized for their respective contents.  283 
On the contrary, the bioavailability of ferulic acid can be evaluated by focusing specifically on 284 
its direct metabolites, such as ferulic acid-4’-O-sulfate, dihydroferulic acid-4’-O-sulfate and 285 
dihydroferulic acid-O-glucuronide, and by correlating their total amount to the amount of 286 
native free and bound ferulic acid provided through each test meal. Fig. 4 shows that the 287 
bioavailability of ferulic acid in aleurone enriched bread containing the same dose of ferulic 288 
acid (AB-190) was slightly higher than after the control wholegrain product, but this 289 
difference did not reach a statistical significance. On the contrary, the bioavailability of 290 








ferulic acid in bread (AB-94) enriched in aleurone fraction consumed in same quantity as 291 
wholegrain bread was significantly higher.  292 
 293 
3.3 Plasma kinetics of phenolic compounds 294 
The second target of the study focused on plasma pharmacokinetics of phenolic compounds 295 
in bread. Contrary to urinary data, only 4 metabolites were detected in quantifiable 296 
concentrations in plasma samples. Hippuric acid and hydroxyhippuric acid (where the 297 
concentration was calculated considering both of the isomers) had the highest 298 
concentration among all circulating metabolites (Supporting information Fig. 3a and b). 299 
Although hippuric acid exhibited a peak plasma concentration at 7 h, indicating a possible 300 
colonic degradation of native phenolic compounds, the absorption curves appeared unclear 301 
and these metabolites could not be directly associated with phenolic acid metabolism. On 302 
the contrary, the presence of ferulic acid-4’-O-sulfate and dihydroferulic acid-4’-O-sulfate 303 
can be strictly linked to bread consumption (Fig. 5). The curve reported for ferulic acid-4’-O-304 
sulfate  (Fig. 5a) clearly demonstrates the absorption and the rapid conjugation of the native 305 
ferulic acid in the first part of the gastrointestinal tract, confirming what was observed in 306 
urines. The evidence was supported by the calculated Tmax value close to 1 h. The circulating 307 
concentrations rapidly decreased within 3 h and progressively until 24 h. Although the curve 308 
derived from the consumption of the product enriched in aleurone fraction containing less 309 
ferulic acid (AB-94) showed a lower Cmax and AUCs value, no significant differences were 310 
observed in the kinetic parameters among the three products. The dihydroferulic acid-4’-O-311 
sulfate absorption curve (Fig. 5b) distinctly outlined a maximum peak at 7 h, which was 312 
higher after the consumption of AB-190, in accordance with its colonic formation [34], and 313 








its concentration decreased before the last collection time point. However, because of the 314 
lack of intermediate time points between 7 h and 24 h it was impossible to exclude the 315 
presence of additional peak concentrations within this period. 316 
 317 
4 DISCUSSION 318 
The present study compared, for the first time, the in vivo human absorption, metabolism 319 
and bioavailability of phenolic compounds present in two types of bread:  wholegrain bread 320 
and wheat bread enriched in aleurone fraction.  We standardized bread intake based on the 321 
dose of the main phenolic acid, ferulic acid, and accounted for free and bound phenolics, as 322 
well as ferulic acid oligomers [27].  323 
Previous research has compared the in vitro early digestion of wholegrain bran to the 324 
aleurone fraction. Zaupa and colleagues reported the in vitro bioaccessibility of the main 325 
phenolic compounds were higher in the aleurone flour compared to unfractionated bran 326 
[26]. These results were corroborated when the same approach was used to measure the in 327 
vitro bioaccessibility of phenolic compounds in wholegrain flour bread or aleurone-rich flour 328 
bread. All the main phenolic acids were significantly more bioaccessible in the bread 329 
enriched in aleurone fraction [27]. Despite small intestine bioaccessibility, it is important to 330 
assess colonic bioaccessibility, as phenolic compounds are poorly absorbed in the small 331 
intestine [23]. In vitro colonic biotransformation has revealed the capacity of colonic 332 
microbiota enzymes to catabolize ferulic oligomers, to release fiber-linked compounds, and 333 
to convert them into simple metabolites, such as ferulic and dihydroferulic acid and other 334 
aromatic metabolites such as phenylpropionic, phenylacetic and benzoic acid derivatives 335 








[18, 35, 36], microbial metabolites which have been reported to be efficiently absorbed at 336 
large intestinal level [37]. 337 
Existing animal studies that fed a whole-wheat meal or aleurone-rich meal led to the 338 
identification of both human and microbial metabolites that are mainly conjugated with 339 
sulfate or glucuronic acid residues [28, 38, 39]. Calani and colleagues (2014) fed rats a 340 
control pellet or a wheat aleurone-rich pellet. Fifteen metabolites were quantified and were 341 
mostly sulfate conjugated. Of these fifteen, six metabolites were detected in the present 342 
human in vivo study including: ferulic acid-4’-O-sulfate, dihydroferulic acid-4’-O-sulfate, 343 
vanillic acid-4-O-sulfate, 3-(phenyl)propionic acid-O-sulfate, 3’,4’-dihydroxyphenylacetic acid 344 
and hippuric acid. In the same rat feeding study the 24-h urinary recovery for the majority of 345 
metabolites was higher when the aleurone-rich pellet was consumed, demonstrating a 346 
higher absorption of aleurone phenolic compounds [28]. A better absorption of the phenolic 347 
acid of aleurone fraction rather than wholegrain was also established by Nørskov and 348 
colleagues (2013). Pigs that consumed aleurone-rich wheat flour for 72 h had a higher 349 
phenolic metabolite plasma concentration in comparison to a whole-wheat diet. However, 350 
the phenolic compound intake was not standardized between the two diets [39].  351 
No human studies are available on aleurone phenolic acid metabolism and absorption. 352 
However, some human intervention studies that investigated wholegrain cereal 353 
consumption reported urinary excretion of ferulic acid conjugates, feruloylglycine and 354 
sinapic acid conjugates [40].  Additionally, plasma circulating concentrations of ferulic acid 355 
conjugates, vanillic acid, 3-(hydroxyphenyl)propionic acid conjugates, and sinapic acid 356 
conjugates [21, 40], have been reported as ranging from nanomolar to low micromolar. The 357 
absence of some plasma microbial catabolites following wholegrain bread intake in the 358 








present study could be explained by the lower dose of ferulic acid (~3-3.5 fold lower 359 
respectively), than previously utilized in other studies.  360 
In the present study we standardized ferulic intake between the wholegrain bread and the 361 
aleurone bread trials and found a total bioavailability of 4-8%. The bioavailability of ferulic 362 
acid in humans was higher than in rats fed aleurone-rich pellets where it was approximately 363 
0.7% [28]. In contrast, ferulic acid bioavailability was similar, at 4-5.5%, when rats were fed a 364 
cereal-based meal [20]. Additionally, other human studies that examined whole-wheat 365 
bread or high-bran cereals report a 3-10% bioavailability of ferulic acid [21, 40]. Other 366 
studies that report wholegrain ferulic acid bioavailability, with the exception of Calani et al 367 
(2014), do not consider the amount of ferulic acid dimers or trimers contained in the test 368 
meal.  369 
As bioavailability could have been influenced both by the type of ferulic acid source 370 
(wholegrain flour or aleurone fraction) and by the amount of bread (with a possible bulk 371 
effect and/or absorption saturation), the chosen study design allowed us to discriminate 372 
between these two potential co-factors. When the same amount of ferulic acid was fed 373 
(87mg, but the two bread amounts were different), the bioavailability did not result 374 
significantly different between aleurone enriched and wholemeal breads (Fig.4), unless 375 
feruloyglycine was accounted for in the calculation (Supporting information Fig. 4). When, 376 
however, the same amount of bread was fed (94g, but the total ferulic acid intake was 377 
different), ferulic acid from aleurone-enriched bread was significantly better absorbed and 378 
excreted. Nevertheless, it must be pointed out that the excretion of feruloylglycine in the 379 
bioavailability calculation could be misleading, since the concentration of this metabolite 380 
was detectable already at the beginning (T0) of each treatment, as also previously reported 381 








[40], suggesting that its 48 h-cumulative excretion could result from the catabolism of other 382 
ingested or biotransformed compounds.   383 
Plasma levels of ferulic acid metabolites were not significantly different after the three 384 
feedings, indicating that even with half dose of ferulic acid (introduced with AB-94),  385 
consumers could reach plasma levels of ferulic acid metabolites comparable to those 386 
obtained from a higher dose introduced through wholemeal bread or higher volumed of 387 
aleurone bread. 388 
The higher ferulic bioavailability in bread enriched with the aleurone fraction compared to 389 
wholegrain bread could be explained by the different bran structure. Increased 390 
bioaccessibility, and hence bioavailability, of wheat aleurone phenolics has been 391 
demonstrated in the literature by applying different approaches, like enzymatic treatments 392 
targeting specific linkages in wheat bran [35, 41], fermentation systems, used as sources of 393 
specific enzymes [21, 41], or high energy grinding, increasing the specific surface of the bran 394 
fractions [16, 35]. Conversely, the higher bioavailability we observed following the lower 395 
ferulic consumption suggests a potential negative dose-metabolic response explained by a 396 
reduction in the capacity to metabolize and absorb phenolic acids caused by a higher level 397 
of intake. Future studies should focus on establishing the mechanisms involved in the 398 
absorption of phenolic acids from aleurone-rich products. 399 
In recent years, the consumption of (poly)phenol-rich foods has been largely connected to 400 
beneficial health effects [42, 43]. As such, evaluating the metabolism and bioavailability of 401 
phenolic acids (particularly ferulic acid) in widely consumed staple products, such as bread, 402 
becomes of particular interest. Additionally, more studies are appearing in the literature 403 
trying to unravel the mechanisms behind the protective effects exerted by wholegrain 404 








foods, with some of these highlighting the possible involvement of phenolic acids. For 405 
example, the circulating levels of specific phenolic metabolites detected after wholegrain 406 
consumption in humans, such as ferulic acid conjugates, vanillic acid and 407 
hydroxyphenylpropionic acid, have been specifically related to a reduction in pro / anti-408 
inflammatory cytokine ratios. These metabolites result in an immune-modulatory effect [21] 409 
and a reduction in TNF-α and an enhancement in IL-10 correlated to the improvement of 410 
the inflammation status [44]. Furthermore, two of the main phenolic acid metabolites (3,4-411 
dihydroxyphenylacetic acid and 3-hydroxyphenylpropionic acid) have been described in vitro 412 
to potentiate glucose-stimulated insulin secretion in a beta cell line INS-1E and in rat 413 
pancreatic islets [45]. Also, these metabolites are reported to protect against beta cell 414 
dysfunction and death induced by tert-butyl hydroperoxide, through the activation of 415 
protein kinase C and the extracellular regulated kinase pathways [45]. Moreover, the 416 
dihydroxylated microbial compound 3,4-dihydroxyphenylacetic acid, as well as 3,4-417 
dihydroxyphenylpropionic, exhibited anti-inflammatory properties, modulating the 418 
production of the main pro-inflammatory cytokines, as TNF-α, IL-1β and IL-6, in LPS-419 
stimulated peripheral blood mononuclear cells. Contrarily, 4-hydroxyhippuric acid exerted 420 
its anti-inflammatory property only acting on TNF-α secretion [46]. Finally, very recently, 421 
Malunga and colleagues described ferulic acid and feruloylated arabinoxylan mono-422 
/oligosaccharides as possible inhibitors of sucrase and maltase functions of α-glucosidase in 423 
Caco-2 and rat intestinal cells; moreover glucose uptake in Caco-2 cells was partially 424 
inhibited by their presence [47]. 425 
Limited evidence is available on potential human health benefits due to aleurone. Rats fed 426 
with wheat aleurone did not experience improvement of any parameter associated with 427 








obesity, such as body weight gain, adiposity, fasting blood glucose, plasma insulin and 428 
leptin, anti-inflammatory markers and oxidative stress markers [48]. Ounnas and colleagues 429 
(2014) demonstrated that plasma eicosapentaenoic acid concentration increased in rats fed 430 
with wheat aleurone, while docosahexaenoic acid and omega-6 fatty acids were not 431 
affected [49]. In humans, the consumption of wheat aleurone-rich foods significantly 432 
lowered the plasma concentration of the inflammatory marker, C-reactive protein, which is 433 
an independent risk factor for CVD. No changes were observed in other markers of 434 
inflammation, antioxidant status or endothelial function [50]. However, it remains to be 435 
established whether the potential health benefits reported for wholegrain consumption are 436 
dependent on a specific component or a combination of components present in wholegrains 437 
and possibly in aleurone fractions. 438 
In conclusion, this is the first human intervention study in which phenolic compound 439 
metabolism, absorption and bioavailability in wholegrain bread have been compared to 440 
those introduced through bread enriched with aleurone layer. The results of this study, 441 
besides showing a general increased bioavailability of ferulic acid in aleurone-rich bread, 442 
demonstrate that high levels of ferulic acid metabolites can be achieved in humans with the 443 
consumption of relatively low amounts (4 slices) of white, aleurone-enriched bread. We are 444 
only able to speculate as if the potential mechanisms behind the health effects linked to 445 
wholegrains are maintained with aleurone-rich food consumption. However, if the 446 
circulating phenolic metabolites after intake of wholegrain products are involved in 447 
physiological benefits [44], this study demonstrates that the same levels could be reached 448 
through consumption of refined products enriched in aleurone fractions. This study paves 449 
the way for future research focused on measuring the modulation of health related 450 








biomarkers by aleurone and its phenolics in both health individuals as well as those with 451 
disease risk factors. 452 
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Nutritional values and ferulic acid content per portion of testing meals. 
 
WGB 










Energy (kcal) 246 245 496 
Energy (kJ) 1035 1035 2092 
Fats (g) 5.5 3.9 8.0 
Carbohydrates (g) 35.3 40.7 82.3 
Fiber (g) 7.5 5.6 11.4 
Proteins (g) 10.2 8.9 18.0 
Ferulic Acid (mg) 87 43 87 
 
TABLE 2 
Standard compounds used for metabolite quantification. 
Metabolites Standard compounds used for quantification 








3’,4’-Dihydroxyphenylacetic acid 3’,4’-Dihydroxyphenylacetic acid 
Hippuric acid Hippuric acid 
4-Hydroxyhippuric acid 
Hydroxyhippuric acid 
4-Hydroxyhippuric acid  
Hydroxybenzoic acid sulfate Dihydrocaffeic acid-3-O-sulfate 
3-(Phenyl)propionic acid-O-
sulfate   
Dihydrocaffeic acid-3-O-sulfate 
Vanillic acid-4-O-sulfate Dihydroferulic acid-4’-O-sulfate 
Feruloylglycine Feruloylglycine 
Dihydrocaffeic acid-3-O-sulfate Dihydrocaffeic acid-3-O-sulfate 
Ferulic acid-4’-O-sulfate Ferulic acid-4’-O-sulfate 
Dihydroferulic acid-4’-O-sulfate Dihydroferulic acid-4’-O-sulfate 
Sinapic acid-O-sulfate Ferulic acid-4’-O-sulfate 
Dihydroferulic acid-O-glucuronide Dihydro(iso)ferulic acid-3-O-glucuronide 
 
TABLE 3 







3’,4’-Dihydroxyphenylacetic acid 2.06 167 123 
 
Urine 
Hippuric acid 2.75 178 134 
 
Urine, Plasma 









Hydroxybenzoic acid sulfate 2.52 217 137 93, 137 Urine 
3-(Phenyl)propionic acid-O-sulfate 2.88 245 165 147, 121 Urine 
Vanillic acid-4-O-sulfate 2.78 247 167 123, 152, 108 Urine 
Feruloylglycine 3.69 250 
206, 100, 149, 
175, 191  
Urine 
Dihydrocaffeic acid-3-O-sulfate 2.55 261 181 137, 119 Urine 
Ferulic acid-4’-O-sulfate 3.53 273 193 149, 178, 134 Urine, Plasma 
Dihydroferulic acid-4’-O-sulfate 2.94 275 195 151, 136, 180, 177 Urine, Plasma 
Sinapic acid-O-sulfate 3.10 303 223 208, 179, 191 Urine 
Dihydroferulic acid-O-glucuronide 3.14 371 195 119, 151, 149, 136 Urine 
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Legends for figures 
FIGURE 1 
Graphical representation of the study design. 
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Cumulative urinary excretion of ferulic acid metabolites: a) Ferulic acid-4’-O-sulfate, b) 
Dihydroferulic acid-4’-O-sulfate, c) Dihydroferulic acid-O-glucuronide, and d) Feruloylglycine. 
Values are expressed as cumulative μmol excreted ± SEM (n = 15). Different letters mean 
significant differences comparing the three consumed product. A general linear model for 
repeated measures (ANOVA, LSD post-hoc test) was used to compare each metabolite 
among the three treatments. Statistical significance was set at p < 0.05. WGB consists of 94 g 
of wholegrain bread, containing approximately 87 mg of total ferulic acid; AB-94 consists of 
94 g of a commercial bread enriched in aleurone fraction, containing approximately 43 mg 
of total ferulic acid; AB-190 consists of 190 g of a commercial bread enriched in aleurone 
fraction, containing approximately 87 mg of total ferulic acid. 
 








FIGURE 3 600 
Cumulative excretion of phenolic acid metabolites: a) Dihydrocaffeic acid-3-O-sulfate, b) 
Sinapic acid sulfate, c) Vanillic acid-4-O-sulfate, and d) Hydroxybenzoic acid sulfate.  Values 
are expressed as cumulative μmol excreted ± SEM (n = 15). Different letters mean significant 
differences comparing the three consumed product. A general linear model for repeated 
measures (ANOVA, LSD post-hoc test) was used to compare each metabolite among the 
three treatments. Statistical significance was set at p < 0.05. WGB consists of 94 g of 
wholegrain bread, containing approximately 87 mg of total ferulic acid; AB-94 consists of 94 
g of a commercial bread enriched in aleurone fraction, containing approximately 43 mg of 
total ferulic acid; AB-190 consists of 190 g of a commercial bread enriched in aleurone 
fraction, containing approximately 87 mg of total ferulic acid. 
 
  601 









Ferulic acid bioavailability calculated comparing the total amount of ferulic acid consumed 
by the 15 volunteers and the quantity excreted through its main metabolites, namely  ferulic 
acid-4’-O-sulfate, dihydroferulic acid-4’-O-sulfate and dihydroferulic acid-O-glucuronide. 
Different letters mean significant differences comparing the three consumed product. A 
general linear model for repeated measures (ANOVA, LSD post-hoc test) was used to 
compare the bioavailability (p < 0.05). WGB consists of 94 g of wholegrain bread, containing 
approximately 87 mg of total ferulic acid; AB-94 consists of 94 g of a commercial bread 
enriched in aleurone fraction, containing approximately 43 mg of total ferulic acid; AB-190 
consists of 190 g of a commercial bread enriched in aleurone fraction, containing 
approximately 87 mg of total ferulic acid. 
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Absorption kinetics of the phenolic metabolites detected in plasma. a) Ferulic acid-4’-O-
sulfate, and b) Dihydroferulic acid-4’-O-sulfate. Values are expressed as nmol/L ± SEM (n = 
5). A general linear model for repeated measures (ANOVA, LSD post-hoc test) was used to 
compare pharmacokinetic parameters among the three treatments. Statistical significance 
was set at p < 0.05. No statistically significant difference was observed. WGB consists of 94 g 
of wholegrain bread, containing approximately 87 mg of total ferulic acid; AB-94 consists of 
94 g of a commercial bread enriched in aleurone fraction, containing approximately 43 mg 
of total ferulic acid; AB-190 consists of 190 g of a commercial bread enriched in aleurone 
fraction, containing approximately 87 mg of total ferulic acid. 
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